Amarin Corporation plc (NASDAQ: AMRN)
Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company, has a lead program entering Phase 3 for hypertriglyceridemia. The company’s cardiovascular programs take advantage of the staff’s expertise in the field of lipid science and the acknowledged therapeutic benefits of essential fatty acids in cardiovascular disease. In addition to Amarin’s lead program, their pipeline includes programs in myasthenia gravis, Huntington’s disease, Parkinson’s disease and epilepsy. For further information, visit the Company's web site at www.amarincorp.com.
